TPG Biotech

TPG Biotech is part of the venture capital investment platform of TPG, the global private investment firm. With more than $500 million under management, TPG Biotech targets investments in life science, biotechnology, renewables and medical technology companies. The firm is backed by the resources of TPG with more than $35 billion of assets under management. www.tpgventures.com/about/tpgb.html, www.tpg.com

Johnson & Johnson Development Corporation

As a division of the one of the world's leading medical and consumer products companies, the Johnson & Johnson Development Corporation (JJDC) provides funding for companies with innovative devices and therapies, biotechnology products, and advanced pharmaceuticals.

Johnson & Johnson has $41.9 billion in sales and is the world's most comprehensive and broadly based manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets. Johnson & Johnson has approximately 110,600 employees and more than 200 operating companies in 57 countries, selling products throughout the world.

The Johnson & Johnson Development Corporation makes equity investments in early-stage venture and young publicly-traded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical and surgical devices, health care information technology, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies. www.jnj.com, www.jjdevcorp.com

MedVenture Associates

Founded in 1986, MedVenture Associates (MVA) is a private venture capital firm specializing in the field of medical technology, including medical devices, instrumentation and medical diagnostic technology. The firm's secondary investment focus is medical information technology, pharmaceutical and biotechnology products and selected later stage investments in all of the firm's areas of investment focus. Investments are made in those areas where the goal is to create significant, substantial new businesses.

Returns to MVA I and MVA II limited partners have been in the top quartile of healthcare funds in the respective years each fund was offered. MVA III has reached the end of its investment cycle. MVA IV started its investment cycle in March 2002.

MVA's goal is to invest in good ideas. Working in partnership with founding entrepreneurs, MVA hopes to turn those ideas into successful companies. www.medven.com

Thomas J. Fogarty, MD

The archetypal physician entrepreneur, Thomas J. Fogarty, MD, has been a driving force in medical device innovation for nearly 40 years. From his first device, invented when he was still in college, until today, Fogarty has been a central figure in global device innovation, with more than seventy patents and more than thirty companies to his name and a host of distinguished awards.

Doctor Fogarty serves as Clinical Professor of Vascular Surgery and Director of Research Development at Stanford Medical School. He is coeditor-in-chief of the Journal of Endovascular Therapy, serves on the editorial boards of several publications, contributed chapters to numerous surgical textbooks and authored over 170 scientific articles in the fields of cardiac, vascular and general surgery.

In 2000 he was awarded the $500,000 Lemelson-MIT Prize, one of the most prestigious honors for inventors and innovators, and in 2001 he was inducted into the National Inventors Hall of Fame.
The Fogarty Institute for Innovation

Quaker BioVentures

Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
http://www.quakerbio.com/